nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—CYP2D6—Parkinson's disease	0.678	1	CbGaD
Vemurafenib—Etoricoxib—CYP2E1—Parkinson's disease	0.00454	0.577	CrCbGaD
Vemurafenib—RAF1—hindbrain—Parkinson's disease	0.0035	0.1	CbGeAlD
Vemurafenib—Etoricoxib—CYP2D6—Parkinson's disease	0.00333	0.423	CrCbGaD
Vemurafenib—RAF1—embryo—Parkinson's disease	0.00219	0.0627	CbGeAlD
Vemurafenib—RAF1—brainstem—Parkinson's disease	0.002	0.0575	CbGeAlD
Vemurafenib—RAF1—forebrain—Parkinson's disease	0.00193	0.0555	CbGeAlD
Vemurafenib—BRAF—midbrain—Parkinson's disease	0.00192	0.055	CbGeAlD
Vemurafenib—RAF1—cardiovascular system—Parkinson's disease	0.00164	0.0469	CbGeAlD
Vemurafenib—BRAF—cerebellum—Parkinson's disease	0.00148	0.0425	CbGeAlD
Vemurafenib—RAF1—medulla oblongata—Parkinson's disease	0.0014	0.0401	CbGeAlD
Vemurafenib—RAF1—midbrain—Parkinson's disease	0.00128	0.0366	CbGeAlD
Vemurafenib—RAF1—spinal cord—Parkinson's disease	0.00125	0.0357	CbGeAlD
Vemurafenib—BRAF—brain—Parkinson's disease	0.0012	0.0345	CbGeAlD
Vemurafenib—RAF1—head—Parkinson's disease	0.00111	0.0318	CbGeAlD
Vemurafenib—RAF1—nervous system—Parkinson's disease	0.00105	0.0301	CbGeAlD
Vemurafenib—RAF1—central nervous system—Parkinson's disease	0.00101	0.029	CbGeAlD
Vemurafenib—CYP2D6—hindbrain—Parkinson's disease	0.000991	0.0284	CbGeAlD
Vemurafenib—RAF1—cerebellum—Parkinson's disease	0.000988	0.0283	CbGeAlD
Vemurafenib—ORM1—spinal cord—Parkinson's disease	0.00086	0.0247	CbGeAlD
Vemurafenib—RAF1—brain—Parkinson's disease	0.000802	0.023	CbGeAlD
Vemurafenib—ORM1—nervous system—Parkinson's disease	0.000725	0.0208	CbGeAlD
Vemurafenib—ORM1—central nervous system—Parkinson's disease	0.000698	0.02	CbGeAlD
Vemurafenib—ABCG2—medulla oblongata—Parkinson's disease	0.000578	0.0166	CbGeAlD
Vemurafenib—CYP2D6—brainstem—Parkinson's disease	0.000568	0.0163	CbGeAlD
Vemurafenib—CYP2D6—forebrain—Parkinson's disease	0.000548	0.0157	CbGeAlD
Vemurafenib—ABCG2—midbrain—Parkinson's disease	0.000528	0.0151	CbGeAlD
Vemurafenib—ABCG2—spinal cord—Parkinson's disease	0.000515	0.0148	CbGeAlD
Vemurafenib—ABCC1—cerebellum—Parkinson's disease	0.000494	0.0142	CbGeAlD
Vemurafenib—ALB—brain—Parkinson's disease	0.000486	0.0139	CbGeAlD
Vemurafenib—ABCG2—cerebellum—Parkinson's disease	0.000409	0.0117	CbGeAlD
Vemurafenib—ABCC1—brain—Parkinson's disease	0.000401	0.0115	CbGeAlD
Vemurafenib—ABCG2—brain—Parkinson's disease	0.000332	0.00952	CbGeAlD
Vemurafenib—CYP2D6—head—Parkinson's disease	0.000314	0.009	CbGeAlD
Vemurafenib—CYP3A4—nervous system—Parkinson's disease	0.000303	0.00867	CbGeAlD
Vemurafenib—CYP2D6—nervous system—Parkinson's disease	0.000298	0.00854	CbGeAlD
Vemurafenib—CYP3A4—central nervous system—Parkinson's disease	0.000291	0.00835	CbGeAlD
Vemurafenib—CYP2D6—central nervous system—Parkinson's disease	0.000287	0.00822	CbGeAlD
Vemurafenib—CYP2D6—cerebellum—Parkinson's disease	0.00028	0.00803	CbGeAlD
Vemurafenib—CYP2D6—brain—Parkinson's disease	0.000228	0.00652	CbGeAlD
Vemurafenib—CYP2D6—Metabolism—ND3—Parkinson's disease	5.93e-05	0.000213	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—MCCC1—Parkinson's disease	5.93e-05	0.000213	CbGpPWpGaD
Vemurafenib—CYP3A4—Metapathway biotransformation—COMT—Parkinson's disease	5.9e-05	0.000211	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	5.9e-05	0.000211	CbGpPWpGaD
Vemurafenib—CYP3A4—Metapathway biotransformation—GSTP1—Parkinson's disease	5.87e-05	0.00021	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PDYN—Parkinson's disease	5.86e-05	0.00021	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—FGB—Parkinson's disease	5.84e-05	0.000209	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—HTR1A—Parkinson's disease	5.81e-05	0.000208	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—HTR7—Parkinson's disease	5.76e-05	0.000206	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—DRD2—Parkinson's disease	5.76e-05	0.000206	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TAC1—Parkinson's disease	5.73e-05	0.000205	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—INS—Parkinson's disease	5.69e-05	0.000204	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—IL6—Parkinson's disease	5.65e-05	0.000203	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—IL6—Parkinson's disease	5.65e-05	0.000203	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—IL6—Parkinson's disease	5.65e-05	0.000203	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—DRD1—Parkinson's disease	5.62e-05	0.000201	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—IL6—Parkinson's disease	5.6e-05	0.000201	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—TALDO1—Parkinson's disease	5.58e-05	0.0002	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—OMD—Parkinson's disease	5.58e-05	0.0002	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—IL6—Parkinson's disease	5.57e-05	0.000199	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—IL6—Parkinson's disease	5.55e-05	0.000199	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—IL6—Parkinson's disease	5.53e-05	0.000198	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—GFAP—Parkinson's disease	5.51e-05	0.000198	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—CTGF—Parkinson's disease	5.51e-05	0.000198	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PLA2G6—Parkinson's disease	5.51e-05	0.000197	CbGpPWpGaD
Vemurafenib—CYP3A4—Biological oxidations—GSTM1—Parkinson's disease	5.47e-05	0.000196	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—MAOB—Parkinson's disease	5.45e-05	0.000195	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—GRM5—Parkinson's disease	5.45e-05	0.000195	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—DBH—Parkinson's disease	5.45e-05	0.000195	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—FBP1—Parkinson's disease	5.45e-05	0.000195	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GBA—Parkinson's disease	5.45e-05	0.000195	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—DRD3—Parkinson's disease	5.44e-05	0.000195	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—ADRBK1—Parkinson's disease	5.43e-05	0.000195	CbGpPWpGaD
Vemurafenib—CYP3A4—Metapathway biotransformation—GSTM1—Parkinson's disease	5.4e-05	0.000193	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G6—Parkinson's disease	5.34e-05	0.000191	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—IL6—Parkinson's disease	5.32e-05	0.000191	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NDUFB11—Parkinson's disease	5.29e-05	0.00019	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—ADRBK1—Parkinson's disease	5.08e-05	0.000182	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GCH1—Parkinson's disease	5.05e-05	0.000181	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ND3—Parkinson's disease	5.03e-05	0.00018	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—MCCC1—Parkinson's disease	5.03e-05	0.00018	CbGpPWpGaD
Vemurafenib—RAF1—Disease—ADRBK1—Parkinson's disease	5.02e-05	0.00018	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—IL6—Parkinson's disease	5.01e-05	0.000179	CbGpPWpGaD
Vemurafenib—RAF1—Disease—HSPA1A—Parkinson's disease	4.98e-05	0.000179	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—ADRBK1—Parkinson's disease	4.97e-05	0.000178	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—HSPA1A—Parkinson's disease	4.94e-05	0.000177	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—HTR7—Parkinson's disease	4.92e-05	0.000176	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—DRD2—Parkinson's disease	4.92e-05	0.000176	CbGpPWpGaD
Vemurafenib—BRAF—Disease—MTHFR—Parkinson's disease	4.91e-05	0.000176	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Parkinson's disease	4.84e-05	0.000173	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FGF20—Parkinson's disease	4.78e-05	0.000171	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—SOD1—Parkinson's disease	4.77e-05	0.000171	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—SLC6A3—Parkinson's disease	4.76e-05	0.000171	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—TALDO1—Parkinson's disease	4.73e-05	0.000169	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—OMD—Parkinson's disease	4.73e-05	0.000169	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ADORA2A—Parkinson's disease	4.64e-05	0.000166	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—EDN1—Parkinson's disease	4.61e-05	0.000165	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CYP2D6—Parkinson's disease	4.61e-05	0.000165	CbGpPWpGaD
Vemurafenib—BRAF—Disease—APOE—Parkinson's disease	4.57e-05	0.000164	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—CYCS—Parkinson's disease	4.57e-05	0.000164	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—ABL1—Parkinson's disease	4.55e-05	0.000163	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—IGF2—Parkinson's disease	4.53e-05	0.000162	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CTGF—Parkinson's disease	4.52e-05	0.000162	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—DBH—Parkinson's disease	4.5e-05	0.000161	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GBA—Parkinson's disease	4.5e-05	0.000161	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—FBP1—Parkinson's disease	4.5e-05	0.000161	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NDUFB11—Parkinson's disease	4.48e-05	0.000161	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—ABL1—Parkinson's disease	4.43e-05	0.000159	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—INSR—Parkinson's disease	4.28e-05	0.000153	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—HGF—Parkinson's disease	4.28e-05	0.000153	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GCH1—Parkinson's disease	4.27e-05	0.000153	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CYP2E1—Parkinson's disease	4.21e-05	0.000151	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—NQO1—Parkinson's disease	4.17e-05	0.000149	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HGF—Parkinson's disease	4.17e-05	0.000149	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IGF2—Parkinson's disease	4.12e-05	0.000148	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—TH—Parkinson's disease	4.1e-05	0.000147	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CYP2D6—Parkinson's disease	4.05e-05	0.000145	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FGB—Parkinson's disease	4.04e-05	0.000145	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—HTR2A—Parkinson's disease	4.03e-05	0.000145	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HTR1A—Parkinson's disease	4.02e-05	0.000144	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—DDC—Parkinson's disease	4e-05	0.000143	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IGF1R—Parkinson's disease	3.98e-05	0.000143	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CTGF—Parkinson's disease	3.98e-05	0.000143	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—HMOX1—Parkinson's disease	3.97e-05	0.000142	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TAC1—Parkinson's disease	3.96e-05	0.000142	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CYCS—Parkinson's disease	3.94e-05	0.000141	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EDN1—Parkinson's disease	3.94e-05	0.000141	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IL6—Parkinson's disease	3.92e-05	0.00014	CbGpPWpGaD
Vemurafenib—BRAF—Disease—INS—Parkinson's disease	3.91e-05	0.00014	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—DRD1—Parkinson's disease	3.88e-05	0.000139	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ND3—Parkinson's disease	3.88e-05	0.000139	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—MCCC1—Parkinson's disease	3.88e-05	0.000139	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—Parkinson's disease	3.86e-05	0.000138	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—IL6—Parkinson's disease	3.85e-05	0.000138	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—ABCB1—Parkinson's disease	3.81e-05	0.000137	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—FBP1—Parkinson's disease	3.81e-05	0.000137	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GBA—Parkinson's disease	3.81e-05	0.000137	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—DBH—Parkinson's disease	3.81e-05	0.000137	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTA4—Parkinson's disease	3.77e-05	0.000135	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—DRD3—Parkinson's disease	3.76e-05	0.000135	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—GPX1—Parkinson's disease	3.73e-05	0.000134	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CYP2E1—Parkinson's disease	3.71e-05	0.000133	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—NQO1—Parkinson's disease	3.66e-05	0.000131	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—TALDO1—Parkinson's disease	3.65e-05	0.000131	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—OMD—Parkinson's disease	3.65e-05	0.000131	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NGF—Parkinson's disease	3.62e-05	0.00013	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—TH—Parkinson's disease	3.61e-05	0.000129	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ADRBK1—Parkinson's disease	3.51e-05	0.000126	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—COMT—Parkinson's disease	3.49e-05	0.000125	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—IL6—Parkinson's disease	3.48e-05	0.000125	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GSTP1—Parkinson's disease	3.47e-05	0.000125	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CYCS—Parkinson's disease	3.47e-05	0.000124	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—MAOA—Parkinson's disease	3.47e-05	0.000124	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NDUFB11—Parkinson's disease	3.46e-05	0.000124	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—HTR2A—Parkinson's disease	3.44e-05	0.000123	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—MAPK8—Parkinson's disease	3.44e-05	0.000123	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—HMOX1—Parkinson's disease	3.43e-05	0.000123	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—DRD2—Parkinson's disease	3.4e-05	0.000122	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HTR7—Parkinson's disease	3.4e-05	0.000122	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PLA2G6—Parkinson's disease	3.4e-05	0.000122	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MTHFR—Parkinson's disease	3.4e-05	0.000122	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MTHFR—Parkinson's disease	3.37e-05	0.000121	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—MAOB—Parkinson's disease	3.36e-05	0.000121	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—DDC—Parkinson's disease	3.3e-05	0.000118	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GCH1—Parkinson's disease	3.3e-05	0.000118	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ABCB1—Parkinson's disease	3.29e-05	0.000118	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—APOE—Parkinson's disease	3.2e-05	0.000115	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	3.2e-05	0.000115	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GSTM1—Parkinson's disease	3.19e-05	0.000114	CbGpPWpGaD
Vemurafenib—RAF1—Disease—APOE—Parkinson's disease	3.16e-05	0.000113	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—APOE—Parkinson's disease	3.14e-05	0.000112	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTA4—Parkinson's disease	3.12e-05	0.000112	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TNF—Parkinson's disease	3.08e-05	0.00011	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—COMT—Parkinson's disease	3.07e-05	0.00011	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GPX1—Parkinson's disease	3.06e-05	0.00011	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GSTP1—Parkinson's disease	3.06e-05	0.00011	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—MAOA—Parkinson's disease	3.05e-05	0.000109	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—HMOX1—Parkinson's disease	3.01e-05	0.000108	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GBA—Parkinson's disease	2.94e-05	0.000105	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—DBH—Parkinson's disease	2.94e-05	0.000105	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—FBP1—Parkinson's disease	2.94e-05	0.000105	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ABCB1—Parkinson's disease	2.89e-05	0.000104	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IGF2—Parkinson's disease	2.85e-05	0.000102	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—MTHFR—Parkinson's disease	2.82e-05	0.000101	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GSTM1—Parkinson's disease	2.81e-05	0.000101	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PLA2G6—Parkinson's disease	2.81e-05	0.000101	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—DDC—Parkinson's disease	2.8e-05	0.0001	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—MAOB—Parkinson's disease	2.78e-05	9.96e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IGF1R—Parkinson's disease	2.76e-05	9.88e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—INS—Parkinson's disease	2.74e-05	9.81e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EDN1—Parkinson's disease	2.72e-05	9.76e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—INS—Parkinson's disease	2.7e-05	9.69e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GPX1—Parkinson's disease	2.69e-05	9.64e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—INS—Parkinson's disease	2.68e-05	9.6e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTA4—Parkinson's disease	2.64e-05	9.46e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—APOE—Parkinson's disease	2.63e-05	9.41e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—Parkinson's disease	2.61e-05	9.34e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NGF—Parkinson's disease	2.5e-05	8.97e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CYP2D6—Parkinson's disease	2.5e-05	8.96e-05	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—IL6—Parkinson's disease	2.49e-05	8.91e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—MTHFR—Parkinson's disease	2.48e-05	8.9e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CTGF—Parkinson's disease	2.45e-05	8.8e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HTR2A—Parkinson's disease	2.38e-05	8.54e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PLA2G6—Parkinson's disease	2.38e-05	8.52e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—MAOB—Parkinson's disease	2.35e-05	8.44e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—APOE—Parkinson's disease	2.31e-05	8.28e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CYP2E1—Parkinson's disease	2.29e-05	8.2e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—NQO1—Parkinson's disease	2.26e-05	8.11e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—INS—Parkinson's disease	2.24e-05	8.04e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	2.24e-05	8.03e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—TH—Parkinson's disease	2.23e-05	7.99e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—APOE—Parkinson's disease	2.22e-05	7.94e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—IL6—Parkinson's disease	2.2e-05	7.87e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL1B—Parkinson's disease	2.18e-05	7.83e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—DDC—Parkinson's disease	2.16e-05	7.73e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CYCS—Parkinson's disease	2.14e-05	7.67e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTA4—Parkinson's disease	2.04e-05	7.3e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CASP3—Parkinson's disease	2.04e-05	7.3e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CTGF—Parkinson's disease	2.03e-05	7.26e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—MAPK8—Parkinson's disease	2e-05	7.18e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—INS—Parkinson's disease	1.97e-05	7.08e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—COMT—Parkinson's disease	1.9e-05	6.79e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—INS—Parkinson's disease	1.89e-05	6.78e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP2E1—Parkinson's disease	1.89e-05	6.77e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTP1—Parkinson's disease	1.89e-05	6.76e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—MAOA—Parkinson's disease	1.88e-05	6.74e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MAPK8—Parkinson's disease	1.87e-05	6.71e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NQO1—Parkinson's disease	1.87e-05	6.69e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—HMOX1—Parkinson's disease	1.86e-05	6.67e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—TH—Parkinson's disease	1.84e-05	6.6e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PLA2G6—Parkinson's disease	1.83e-05	6.58e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—MAOB—Parkinson's disease	1.82e-05	6.51e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ABCB1—Parkinson's disease	1.79e-05	6.4e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYCS—Parkinson's disease	1.77e-05	6.33e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP2D6—Parkinson's disease	1.75e-05	6.27e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTM1—Parkinson's disease	1.73e-05	6.21e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CTGF—Parkinson's disease	1.72e-05	6.15e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—IL6—Parkinson's disease	1.71e-05	6.12e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GPX1—Parkinson's disease	1.66e-05	5.95e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP2E1—Parkinson's disease	1.6e-05	5.73e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NQO1—Parkinson's disease	1.58e-05	5.67e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—COMT—Parkinson's disease	1.56e-05	5.61e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—TH—Parkinson's disease	1.56e-05	5.59e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTP1—Parkinson's disease	1.56e-05	5.58e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—MAOA—Parkinson's disease	1.55e-05	5.57e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—HMOX1—Parkinson's disease	1.54e-05	5.51e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—MTHFR—Parkinson's disease	1.53e-05	5.49e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYCS—Parkinson's disease	1.5e-05	5.36e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ABCB1—Parkinson's disease	1.47e-05	5.28e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTM1—Parkinson's disease	1.43e-05	5.13e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—APOE—Parkinson's disease	1.43e-05	5.11e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CASP3—Parkinson's disease	1.41e-05	5.05e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL6—Parkinson's disease	1.4e-05	5.02e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GPX1—Parkinson's disease	1.37e-05	4.91e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP2D6—Parkinson's disease	1.35e-05	4.84e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—COMT—Parkinson's disease	1.33e-05	4.75e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CTGF—Parkinson's disease	1.33e-05	4.75e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTP1—Parkinson's disease	1.32e-05	4.73e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—MAOA—Parkinson's disease	1.32e-05	4.72e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—HMOX1—Parkinson's disease	1.3e-05	4.66e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MAPK8—Parkinson's disease	1.3e-05	4.64e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL6—Parkinson's disease	1.28e-05	4.59e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—MTHFR—Parkinson's disease	1.26e-05	4.53e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ABCB1—Parkinson's disease	1.25e-05	4.48e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP2E1—Parkinson's disease	1.23e-05	4.43e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NQO1—Parkinson's disease	1.22e-05	4.38e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—INS—Parkinson's disease	1.22e-05	4.37e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTM1—Parkinson's disease	1.21e-05	4.35e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—TH—Parkinson's disease	1.2e-05	4.31e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL6—Parkinson's disease	1.2e-05	4.28e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IL6—Parkinson's disease	1.18e-05	4.23e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—APOE—Parkinson's disease	1.18e-05	4.22e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IL6—Parkinson's disease	1.17e-05	4.2e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GPX1—Parkinson's disease	1.16e-05	4.16e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYCS—Parkinson's disease	1.16e-05	4.14e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—MTHFR—Parkinson's disease	1.07e-05	3.84e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—COMT—Parkinson's disease	1.02e-05	3.67e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTP1—Parkinson's disease	1.02e-05	3.65e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—MAOA—Parkinson's disease	1.02e-05	3.64e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—INS—Parkinson's disease	1.01e-05	3.61e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HMOX1—Parkinson's disease	1e-05	3.6e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—APOE—Parkinson's disease	9.98e-06	3.58e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ABCB1—Parkinson's disease	9.64e-06	3.45e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTM1—Parkinson's disease	9.36e-06	3.35e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GPX1—Parkinson's disease	8.96e-06	3.21e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—INS—Parkinson's disease	8.52e-06	3.05e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6—Parkinson's disease	8.27e-06	2.96e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—MTHFR—Parkinson's disease	8.27e-06	2.96e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—APOE—Parkinson's disease	7.7e-06	2.76e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—INS—Parkinson's disease	6.58e-06	2.36e-05	CbGpPWpGaD
